|Bid||7.15 x 1800|
|Ask||7.99 x 900|
|Day's Range||7.44 - 7.92|
|52 Week Range||2.94 - 11.73|
|Beta (5Y Monthly)||2.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.00|
Trial Advancing on Schedule and Second Patient Dosed in Cohort 7No Evidence of Drug-Induced Anti-Drug Antibodies Observed to DateSEATTLE, WA / ACCESSWIRE / September 1, 2020 / Aptevo Therapeutics Inc.
* Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Complete * Presents New Preclinical Data Showing That ALG.
Extends Cash Runway into Q3 2021The Current Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436 Phase I(a) Dosing Cohorts Which Pre-Clinical Modelling Predicts May Deliver an Efficacious DoseSEATTLE, WA / ACCESSWIRE / August 6, 2020 / Aptevo Therapeutics Inc.